anastrozole has been researched along with Gynecomastia in 21 studies
Gynecomastia: Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning." | 9.11 | Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. ( Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F, 2005) |
| "A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain." | 9.11 | Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. ( Gallo, J; Morris, T; Saltzstein, D; Sieber, P, 2005) |
| "A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life." | 9.11 | Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. ( Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A, 2005) |
| "Our objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of anastrozole in adolescent males with gynecomastia of less than 1 yr duration." | 7.75 | Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. ( Agbo, F; Bishop, K; Emeribe, U; Lowe, E; Mauras, N; Merinbaum, D, 2009) |
| "Anastrozole treatment was well tolerated." | 6.71 | Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. ( Backeljauw, PF; Bercu, BB; Desrochers, PE; Diamond, FB; Jou, HC; Plourde, PV; Reiter, EO; Rubin, SD, 2004) |
| " After 2 years of treatment, anastrozole is still currently used at a dosage of 1 mg once daily with no side effects." | 5.37 | Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study. ( Cirillo, G; Coppola, F; del Giudice, EM; Grandone, A; Perrone, L; Santarpia, M, 2011) |
| "Gynecomastia is an unusual side effect associated with testosterone replacement therapy (TRT) that has been traditionally treated with surgery, radiation, or discontinuation of testosterone supplementation." | 5.32 | Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. ( Morgentaler, A; Rhoden, EL, 2004) |
| "To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning." | 5.11 | Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. ( Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F, 2005) |
| "A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain." | 5.11 | Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. ( Gallo, J; Morris, T; Saltzstein, D; Sieber, P, 2005) |
| "A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life." | 5.11 | Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. ( Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A, 2005) |
| "Growth velocity decreased and gynecomastia diminished during anastrozole treatment." | 3.79 | Management of prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy. ( Cataldo, C; D'Andrea, F; De Francesco, F; del Giudice, EM; Di Grezia, G; Ferraro, GA; Gatta, G; Grandone, A; Nicoletti, G; Perrone, L; Romano, T, 2013) |
| "Our objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of anastrozole in adolescent males with gynecomastia of less than 1 yr duration." | 3.75 | Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. ( Agbo, F; Bishop, K; Emeribe, U; Lowe, E; Mauras, N; Merinbaum, D, 2009) |
| "Anastrozole treatment was well tolerated." | 2.71 | Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. ( Backeljauw, PF; Bercu, BB; Desrochers, PE; Diamond, FB; Jou, HC; Plourde, PV; Reiter, EO; Rubin, SD, 2004) |
| "Treatment with anastrozole was stopped after 5." | 1.62 | Long-term Effect of Aromatase Inhibition in Aromatase Excess Syndrome. ( Binder, G; Fukami, M; Nagasaki, K; Nakamura, A; Ogata, T; Schweizer, R, 2021) |
| " After 2 years of treatment, anastrozole is still currently used at a dosage of 1 mg once daily with no side effects." | 1.37 | Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study. ( Cirillo, G; Coppola, F; del Giudice, EM; Grandone, A; Perrone, L; Santarpia, M, 2011) |
| "Gynecomastia is an unusual side effect associated with testosterone replacement therapy (TRT) that has been traditionally treated with surgery, radiation, or discontinuation of testosterone supplementation." | 1.32 | Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. ( Morgentaler, A; Rhoden, EL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kağızmanlı, GA | 1 |
| Besci, Ö | 1 |
| Acinikli, KY | 1 |
| Şeker, G | 1 |
| Yaşar, E | 1 |
| Öztürk, Y | 1 |
| Demir, K | 1 |
| Böber, E | 1 |
| Abacı, A | 1 |
| Moon, JE | 1 |
| Ko, CW | 1 |
| Yang, JD | 1 |
| Lee, JS | 1 |
| Ghadjar, P | 1 |
| Aebersold, DM | 1 |
| Albrecht, C | 1 |
| Böhmer, D | 1 |
| Flentje, M | 1 |
| Ganswindt, U | 1 |
| Höcht, S | 1 |
| Hölscher, T | 1 |
| Müller, AC | 1 |
| Niehoff, P | 1 |
| Pinkawa, M | 1 |
| Sedlmayer, F | 1 |
| Zips, D | 1 |
| Wiegel, T | 1 |
| Binder, G | 1 |
| Nakamura, A | 1 |
| Schweizer, R | 1 |
| Ogata, T | 1 |
| Fukami, M | 1 |
| Nagasaki, K | 1 |
| Simões-Pereira, J | 1 |
| Santos, F | 1 |
| Lopes, L | 1 |
| Limbert, C | 1 |
| Ferraro, GA | 1 |
| Romano, T | 1 |
| De Francesco, F | 1 |
| Grandone, A | 2 |
| D'Andrea, F | 2 |
| del Giudice, EM | 2 |
| Cataldo, C | 1 |
| Gatta, G | 1 |
| Di Grezia, G | 1 |
| Perrone, L | 2 |
| Nicoletti, G | 1 |
| Grella, E | 1 |
| La Padula, S | 1 |
| Romanucci, V | 1 |
| Nicoletti, GF | 1 |
| Crocker, MK | 1 |
| Gourgari, E | 1 |
| Lodish, M | 1 |
| Stratakis, CA | 1 |
| Koç Yekedüz, M | 1 |
| Şıklar, Z | 1 |
| Burgu, B | 1 |
| Kuloğlu, Z | 1 |
| Kocaay, P | 1 |
| Çamtosun, E | 1 |
| İsakoca, M | 1 |
| Kansu, A | 1 |
| Soygür, T | 1 |
| Berberoğlu, M | 1 |
| Mauras, N | 1 |
| Bishop, K | 1 |
| Merinbaum, D | 1 |
| Emeribe, U | 1 |
| Agbo, F | 1 |
| Lowe, E | 1 |
| Maidment, SL | 1 |
| Cirillo, G | 1 |
| Santarpia, M | 1 |
| Coppola, F | 1 |
| Shozu, M | 1 |
| Sebastian, S | 1 |
| Takayama, K | 1 |
| Hsu, WT | 1 |
| Schultz, RA | 1 |
| Neely, K | 1 |
| Bryant, M | 1 |
| Bulun, SE | 1 |
| Rhoden, EL | 1 |
| Morgentaler, A | 1 |
| Riepe, FG | 1 |
| Baus, I | 1 |
| Wiest, S | 1 |
| Krone, N | 1 |
| Sippell, WG | 1 |
| Partsch, CJ | 1 |
| Plourde, PV | 1 |
| Reiter, EO | 1 |
| Jou, HC | 1 |
| Desrochers, PE | 1 |
| Rubin, SD | 1 |
| Bercu, BB | 1 |
| Diamond, FB | 1 |
| Backeljauw, PF | 1 |
| Boccardo, F | 2 |
| Rubagotti, A | 2 |
| Battaglia, M | 1 |
| Di Tonno, P | 1 |
| Selvaggi, FP | 1 |
| Conti, G | 2 |
| Comeri, G | 1 |
| Bertaccini, A | 1 |
| Martorana, G | 1 |
| Galassi, P | 1 |
| Zattoni, F | 1 |
| Macchiarella, A | 1 |
| Siragusa, A | 1 |
| Muscas, G | 1 |
| Durand, F | 1 |
| Potenzoni, D | 2 |
| Manganelli, A | 2 |
| Ferraris, V | 1 |
| Montefiore, F | 1 |
| Saltzstein, D | 1 |
| Sieber, P | 1 |
| Morris, T | 1 |
| Gallo, J | 1 |
| Del Monaco, D | 1 |
| Thönnessen, D | 1 |
| Wenz, F | 1 |
| Lefevre, H | 1 |
| Bouvattier, C | 1 |
| Lahlou, N | 1 |
| Adamsbaum, C | 1 |
| Bougnères, P | 1 |
| Carel, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys With Gynecomastia of Recent Onset[NCT00241436] | Phase 2 | 35 participants | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for anastrozole and Gynecomastia
| Article | Year |
|---|---|
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
Topics: Adenocarcinoma; Anastrozole; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormo | 2020 |
Question 2. Which medications effectively reduce pubertal gynaecomastia?
Topics: Anastrozole; Aromatase Inhibitors; Child; Estrogen Antagonists; Evidence-Based Medicine; Gynecomasti | 2010 |
5 trials available for anastrozole and Gynecomastia
| Article | Year |
|---|---|
Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Dehydroepiandrosterone Sulfate; Estrogens; Gynecomast | 2004 |
Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Anastrozole; Child; Double-Blind Method; Enzyme Inhibitors; Estradiol; Gynecomastia; Hum | 2004 |
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; | 2005 |
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormon | 2005 |
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormona | 2005 |
14 other studies available for anastrozole and Gynecomastia
| Article | Year |
|---|---|
Efficacy of aromatase inhibitor therapy in a case with large cell calcifying Sertoli cell tumour-associated prepubertal gynaecomastia.
Topics: Anastrozole; Aromatase Inhibitors; Child; Gynecomastia; Humans; Male; Peutz-Jeghers Syndrome; Sertol | 2022 |
Combined surgical and medical treatment in an adolescent with severe gynecomastia due to excessive estradiol secretion: a case report.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Combined Modality Therapy; Estradiol; Gynecomastia; H | 2019 |
Long-term Effect of Aromatase Inhibition in Aromatase Excess Syndrome.
Topics: 46, XX Disorders of Sex Development; Adolescent; Anastrozole; Aromatase; Aromatase Inhibitors; Body | 2021 |
Prepubertal gynaecomastia in a boy with Peutz-Jeghers syndrome: managing the aromatase overexpression.
Topics: Anastrozole; Aromatase Inhibitors; Child, Preschool; Gynecomastia; Humans; Male; Peutz-Jeghers Syndr | 2018 |
Management of prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy.
Topics: Adrenal Glands; Anastrozole; Aromatase Inhibitors; Child; Combined Modality Therapy; Comorbidity; Di | 2013 |
Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: clinical and surgical management.
Topics: Anastrozole; Aromatase Inhibitors; Breast; Child; Combined Modality Therapy; Disease Progression; Di | 2013 |
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Topics: AMP-Activated Protein Kinase Kinases; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone | 2014 |
Response to Anastrozole Treatment in a Case with Peutz-Jeghers Syndrome and a Large Cell Calcifying Sertoli Cell Tumor.
Topics: Anastrozole; Aromatase Inhibitors; Child; Gynecomastia; Humans; Male; Nitriles; Peutz-Jeghers Syndro | 2017 |
Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Breast; Child; Gynecomastia; Humans; Male; Nitriles; | 2009 |
Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study.
Topics: Anastrozole; Aromatase Inhibitors; Child; Diseases in Twins; Genetics; Gynecomastia; Humans; Male; N | 2011 |
Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene.
Topics: Adipose Tissue; Adolescent; Adult; Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Ba | 2003 |
Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.
Topics: Adult; Anastrozole; Androgens; Aromatase Inhibitors; Enzyme Inhibitors; Gynecomastia; Humans; Hypogo | 2004 |
Radiotherapeutic prophylaxis of gynecomastia.
Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; | 2005 |
Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.
Topics: Anastrozole; Anti-Mullerian Hormone; Aromatase Inhibitors; Child; DNA; Female; Glycoproteins; Gyneco | 2006 |